Modified Long-Acting UCN2 Promotes Fat Mass Loss While Preserving Skeletal Muscle Mass and Function in Mouse Models of Pharmacological Weight Loss and Sarcopenic Obesity

No approved pharmacotherapy simultaneously reduces excess adiposity and preserves skeletal muscle mass and function. Such an agent would have two distinct applications: improvement of the quality of pharmacological weight loss and treatment of sarcopenic obesity. Urocortin 2 (UCN2) and its receptor corticotropin-releasing hormone receptor 2 (CRHR2) are highly expressed in skeletal muscle, where they regulate hypertrophy and metabolism. Here we show that a modified long-acting acylated UCN2 peptide reduces fat mass while preserving muscle mass and enhancing function across distinct mouse models. Pair-feeding showed these effects were independent of reduced food intake. Combined with the GLP-1 receptor agonist semaglutide or the GIP/GLP-1/glucagon triple agonist retatrutide, UCN2 produced the greatest magnitude of fat loss while preserving lean and muscle mass and increasing in vivo force production, and this gain persisted 4 weeks after dosing stopped. UCN2 increased energy expenditure, prevented the adaptive fall in expenditure caused by reduced food intake, and promoted whole-body fatty acid oxidation. In a sarcopenic obese mouse model, UCN2 reduced fat mass while increasing muscle mass, muscle function, and myofibrillar protein synthesis. These findings identify UCN2-CRHR2 signaling as a strategy to uncouple fat loss from muscle loss, both as a standalone therapy for sarcopenic obesity and as a combination partner with incretins.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-19
DOI
https://doi.org/10.64898/2026.11.12.766237
Primary Topic
Muscle Physiology and Disorders
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Modified Long-Acting UCN2 Promotes Fat Mass Loss While Preserving Skeletal Muscle Mass and Function in Mouse Models of Pharmacological Weight Loss and Sarcopenic Obesity

Mark R. Wade, Jennifer R. Gamarra, Joseph A. Baur, Emmanuel Akoto et al.
bioRxiv (Cold Spring Harbor Laboratory)
Muscle Physiology and Disorders
preprint

Modified Long-Acting UCN2 Promotes Fat Mass Loss While Preserving Skeletal Muscle Mass and Function in Mouse Models of Pharmacological Weight Loss and Sarcopenic Obesity

Mark R. Wade, Jennifer R. Gamarra, Joseph A. Baur, Emmanuel Akoto, Joseph T. Brozinick, Elizabeth R. M. Zunica, Jill A. Willency, Benjamin F. Miller, Christopher L. Axelrod, John P. Kirwan, Paul M. Titchenell, Elizabeth C. Heintz, Pablo Vidal, Valentina Pirro, Corey D. Holman, Samantha G. L. Keyser, Wagner S. Dantas, Gabriel Gaidosh, Analisa L. Taylor, Dylan C. Seiler, Linsey Peed, Patricia A.M. Baumgarten, Steve M. Bauer
preprint en

Abstract

No approved pharmacotherapy simultaneously reduces excess adiposity and preserves skeletal muscle mass and function. Such an agent would have two distinct applications: improvement of the quality of pharmacological weight loss and treatment of sarcopenic obesity. Urocortin 2 (UCN2) and its receptor corticotropin-releasing hormone receptor 2 (CRHR2) are highly expressed in skeletal muscle, where they regulate hypertrophy and metabolism. Here we show that a modified long-acting acylated UCN2 peptide reduces fat mass while preserving muscle mass and enhancing function across distinct mouse models. Pair-feeding showed these effects were independent of reduced food intake. Combined with the GLP-1 receptor agonist semaglutide or the GIP/GLP-1/glucagon triple agonist retatrutide, UCN2 produced the greatest magnitude of fat loss while preserving lean and muscle mass and increasing in vivo force production, and this gain persisted 4 weeks after dosing stopped. UCN2 increased energy expenditure, prevented the adaptive fall in expenditure caused by reduced food intake, and promoted whole-body fatty acid oxidation. In a sarcopenic obese mouse model, UCN2 reduced fat mass while increasing muscle mass, muscle function, and myofibrillar protein synthesis. These findings identify UCN2-CRHR2 signaling as a strategy to uncouple fat loss from muscle loss, both as a standalone therapy for sarcopenic obesity and as a combination partner with incretins.

bioRxiv (Cold Spring Harbor Laboratory)
Pennington Biomedical Research Center (US), Eli Lilly (United States) (US), Oklahoma Medical Research Foundation (US), University of Pennsylvania (US), University of Oklahoma (US)
Muscle Physiology and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon